^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TEST:
Blueprint Genetics Comprehensive Hereditary Cancer Panel

Type:
Laboratory Developed Test
Related tests:
Evidence

News

2years
CUTANEOUS EWING SARCOMA PRESENTING AS A SECOND PRIMARY MALIGNANCY: A CASE REPORT (ASPHO 2022)
"To date, occurrences of bone or soft tissue Ewing sarcoma as a second malignancy have been noted following prior chemotherapy administration. The patient we report here had a rare cutaneous Ewing sarcoma as a second primary cancer a decade after having neuroblastoma treated with surgery only, raising concern for germline-based cancer predisposition. Whole exome sequencing was recommended given the negative sequencing panel result."
Clinical
|
WT1 (WT1 Transcription Factor) • EWSR1 (EWS RNA Binding Protein 1) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • SOX10 (SRY-Box 10) • VIM (Vimentin) • FLI1 (Fli-1 Proto-Oncogene ETS Transcription Factor) • CD99 (CD99 Molecule) • KRT20 (Keratin 20) • SYP (Synaptophysin)
|
PTPRC expression • VIM expression
|
Blueprint Genetics Comprehensive Hereditary Cancer Panel